Tech Company Financing Transactions
Gero Funding Round
Gero, operating out of Singapore, secured $6 million in funding from private investors, Melnichek Investments and VitaDAO.
Transaction Overview
Company Name
Announced On
10/18/2023
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
133 Cecil Street, Keck Seng Tower 14-01
Singapore, 069535
SG
Singapore, 069535
SG
Phone
Undisclosed
Website
Email Address
Overview
We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases. We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Fedichev
Co-Founder
Maxim Kholin
Browse more venture capital transactions:
Prev: 10/18/2023: Flanks venture capital transaction
Next: 10/18/2023: Roofr venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs